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risk factor for the development of signiﬁcant and advanced
ﬁbrosis. Their alterations during antiviral treatment allow
monitoring the progression of liver ﬁbrosis.
doi:10.1016/j.ijid.2010.02.199814th International Congress on Infectious Diseases (ICID) Abs
occult HBV infection isn’t frequent in Iranian thalassemic
patients who suffering from chronic HCV infection.
doi:10.1016/j.ijid.2010.02.1996
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Background: Genomic mutations presented during hep-
atitis B virus (HBV) reverse transcription could explain its
genetic diversity and account for genetically distinct eight
genotypes which show distinctive geographically distribu-
tion. The main objectives of this study were to determinate
the prevalence of hepatitis B virus genotypes in asymp-
tomatic chronic hepatitis B patients without treatment,
and to identify mutations associated to nucleos(t)ides ana-
logues.
Methods: Twenty two serum samples from asymptomatic
chronic hepatitis B patients without treatment were ana-
lyzed using INNO-LIPA HBV Genotyping assay and INNO-LIPA
HBV DRv2 assay (Innogenetics). Nucleic acid was isolated
and quantiﬁed using real time PCR assay COBAS Taqman HBV
test. HBsAg, anti-HBs, HBeAg and anti-HBe were determined
by ADVIA Centaur.
Results: Genotype D was the most prevalent (45.5%) fol-
lowed by genotype A (27.3%) and genotype E (9%). There
were four coinfection cases (18.2%) (two D/H, one E/F and
one A/D genotypes). Both patients infected with genotype
E were from sub-Saharan area. In our study, all the patients
were positive for HBsAg and negative for HBeAg. HBV-DNA
levels were quantiﬁed and themean was 3.4 log10 copies/ml
(minimum 1.07 and maximum 7.04). Among the twenty two
HBV chronic inactive carriers, in only one case was detected
a single mutation in rtV214A position, which has been asso-
ciated to adefovir dipivoxil treatment. In this case, patient
was infected with genotype D. In the remaining patients no
mutations were identiﬁed at reverse transcriptase domain.
Risk factors for HBV acquisition were as follow: vertical
(27.3%), transfusion (13.6%), sexual (9.1%), tattoos (4.5%),
interfamilial (4.5%) and unknown (41%).
Conclusion: INNO-LIPA is a convenient tool for detec-
tion HBV genotype and resistance mutation. Genotype D
was the most prevalent accompanied with genotype A in
asymptomatic patients, but also coinfection genotypes are
frequent. A resistant mutation is rare in asymptomatic
patients but it was detected in one patient, indicating a
possible predisposition to adefovir dipivoxil therapy resis-
tance. HBV reverse transcriptase gene sequencing analysis
provides additional insight as part of monitoring program
that includes genotypic analysis and quantiﬁcation of circu-
lating virus.
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ntiviral treatment with interferon alpha and ribavirin
nﬂuences serum markers of liver ﬁbrosis in children with
hronic hepatitis C
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Background: Liver ﬁbrosis largely inﬂuences the course
nd prognosis of chronic hepatitis C (CHC). Although per-
utaneous liver biopsy is a valuable tool in the evaluation
f liver injury, it posses signiﬁcant drawbacks that limit
epeated use of this technique. The aim of this study was
o assess chosen serum markers of liver ﬁbrosis — laminin
LAM), hyaluronic acid (HA) and transforming growth factor
eta 1 (TGF-beta-1) with their relation to histopathological
ndings as well as their alterations after antiviral treatment
ith recombinant interferon alpha (IFN-alpha) and ribavirin
Rib) in children with CHC.
Methods: Study group included 68 children, age range
—18 years (mean 13,34± 3,27 years) with diagnosed CHC.
istory data were analysed. Diagnosis was conﬁrmed by the
resence of HCV-RNA in serum by RT-PCR. All children under-
ent histopathological evaluation of liver biopsy specimen
ccording to Ishak scoring system. Serum sample and liver
iopsy specimen were collected the same day. LAM, HA
nd TGF-beta-1 were measured in serum by enzyme linked
mmunosorbent assay kits. Children were treated with IFN-
lpha (3 MU/m2 3 x/week in s.c. injections) and Rib (orally,
wice daily) for 48 weeks. Serum markers of ﬁbrosis were
lso assessed at the end of the treatment.
Results: Length of infection was 7.34± 4.03 years (range
—13.5 years). Mean ALT activity was 60,82± 65,02 IU/l.
ncreasing mean serum TGF-beta-1 (p = 0.029) and decreas-
ng mean LAM level (p = 0.039) was found in the groups of
hildren with increasing stage of ﬁbrosis. Level of LAM was
eﬁned a risk factor of signiﬁcant ﬁbrosis (95%CI 18.05;
7.87, p = 0.001), while level of TGF-beta -1 of signiﬁ-
ant (95%CI: -33.51;-1.73, p = 0.030) and progressed liver
brosis (95%CI -36.09; -3.37, p = 0.019). Conducted antivi-
al treatment with IFN-alpha and Rib resulted in signiﬁcant
ecrease of TGF-beta-1 (51.42± 30.68 vs. 35.24± 31.50
g/ml, p = 0.032) and increase of LAM (60.26± 52.38 vs.
3.70± 46.25 ng/ml, p = 0.002) in serum. No signiﬁcant
lterations were detected in the control group of untreated
hildren.
Conclusion: Level of liver injury in children with CHC
aries in severity. TGF-beta-1 and LAM are not only propor-
ional to the stage of ﬁbrosis but also seem to be a good
